Page Image

Aggressive B-Cell Lymphoma

The latest news, research, and perspectives in aggressive B-cell lymphoma. These fast-growing non-Hodgkin lymphomas, including diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma, arise at different stages of B-cell development.

Advertisement
Advertisement
Melissa BadamoPrint | February 8, 2024
This manufacturing process change results in a shorter manufacturing time for axi-cel from 16 days to 14 days.
Read More
Patrick DalyPrint | February 7, 2024
ZUMA-7 showed that axi-cel significantly improved OS compared with standard of care in relapsed or refractory LBCL.
Blood Cancer TalksBlood Cancer Talks | January 31, 2024
Dr. Eyre and the hosts discuss lymphoma abstracts from ASH 2023, including the FLAIR trial and the SYMPATICO trial.
Patrick DalyAggressive B-Cell Lymphoma | December 16, 2023
The study included 16 baseline and 18 post-infusion tumor samples from 26 patients.
Chadi Nabhan, MD, MBA, FACPAggressive B-Cell Lymphoma | December 14, 2023
In this episode of The HemOnc Pulse, Alan Skarbnik, MD, of Novant Health, discusses practice-changing research in DLBCL.
Leah SherwoodAggressive B-Cell Lymphoma | December 14, 2023
The results were presented at the 65th American Society of Hematology Annual Meeting & Exposition in San Diego.
Blood Cancers Today Staff WritersAggressive B-Cell Lymphoma | February 2, 2024
Researchers collected serial peripheral blood mononuclear cell samples from patients with R/R LBCL treated with axi-cel.
Kerri FitzgeraldAggressive B-Cell Lymphoma | December 13, 2023
The phase II, multicenter, single-arm study is assessing axi-cel for frontline treatment in patients with high-risk LBCL.
Kerri FitzgeraldAggressive B-Cell Lymphoma | December 13, 2023
The analysis assessed the impacts of bridging therapy when used in patients receiving axi-cel for large B-cell lymphoma.
Jay Spiegel, MDAggressive B-Cell Lymphoma | December 14, 2023
Dr. Spiegel shared five-year data from a retrospective study of 298 patients with LBCL who received axi-cel.
Peter Riedell, MDAggressive B-Cell Lymphoma | December 12, 2023
Polatuzumab-based bridging was associated with high overall response rate and complete response rate.
Chadi Nabhan, MD, MBA, FACPAggressive B-Cell Lymphoma | December 14, 2023
The SEER database was used to examine disparities in incidence and survival outcomes between different races.
Alison Sehgal, MDAggressive B-Cell Lymphoma | December 12, 2023
Liso-cel "should continue to be a really good option for these older patients," Dr. Sehgal said.
Julie Vose, MD, MBAAggressive B-Cell Lymphoma | December 11, 2023
Julie Vose, MD, MBA, discussed the use of epcoritamab in patients with diffuse large B-cell lymphoma (DLBCL).
Emily HayesAggressive B-Cell Lymphoma | December 13, 2023
Adults older than 65 and newly diagnosed with DLBCL or DLBCL/high-grade BCL with MYC and BCL2 rearrangements were surveyed.
Emily HayesAggressive B-Cell Lymphoma | December 13, 2023
Researchers examined registry data for patients with previously untreated DLBCL or high-grade BCL treated with R-CHOP.
Melissa BadamoAggressive B-Cell Lymphoma | December 5, 2023
One-time liso-cel infusion demonstrated durable responses in R/R LBCL.
Patrick DalyAggressive B-Cell Lymphoma | December 13, 2023
After a median of four years of follow-up, participants in the pivotal ZUMA-2 study had a median OS of nof nearly five years.
Blood Cancer TalksBlood Cancer Talks | December 5, 2023
Dr. Dickinson joins "Blood Cancer Talks" hosts to discuss phase I and II trials on DLBCL, follicular lymphoma, and more.
Emily HayesAggressive B-Cell Lymphoma | December 1, 2023
Extrachromosomal DNA was highly expressed in 18 DLBCL cell lines and may function as a powerful prognostic indicator.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | December 19, 2023
Grzegorz Nowakowski, MD, recounts his experience serving on the FDA ODAC while reviewing the POLARIX data.
Advertisement
Advertisement
Latest News

March 1, 2024